BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Méndez-Sánchez N, Chávez-Tapia NC, Villa AR, Sánchez-Lara K, Zamora-Valdés D, Ramos MH, Uribe M. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11(12): 1737-1741 [PMID: 15793855 DOI: 10.3748/wjg.v11.i12.1737]
URL: https://www.wjgnet.com/1007-9327/full/v11/i12/1737.htm
(0) (0) (4625) (38)
Number Citing Articles
1
Suleyman Aydin. Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors?. Annals of Hepatology 2012; 11(1) doi: 10.1016/S1665-2681(19)31501-7
2
Ancha Baranova, Aybike Birerdinc, Zobair M. Younossi. Adipose Tissue and Adipokines in Health and Disease. 2014;  doi: 10.1007/978-1-62703-770-9_17
3
Nahum Méndez‐Sánchez, Marco Arrese, Daniel Zamora‐Valdés, Misael Uribe. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver International 2007; 27(4) doi: 10.1111/j.1478-3231.2007.01483.x
4
Marion Flechtner-Mors, Samuel N George, Suemeyra Oeztuerk, Mark M Haenle, Wolfgang Koenig, Armin Imhof, Bernhard O Boehm, Tilmann Graeter, Richard A Mason, Wolfgang Kratzer, Atilla S Akinli. Association of adiponectin with hepatic steatosis: a study of 1,349 subjects in a random population sample. BMC Research Notes 2014; 7(1) doi: 10.1186/1756-0500-7-207
5
N.C. Chavez-Tapia, F. Sanchez-Avila, F. Vasquez-Fernandez, A. Torres-Machorro, F.I. Tellez-Avila, M. Uribe. Non-Alcoholic Fatty-Liver Disease in Pediatric Populations. Journal of Pediatric Endocrinology and Metabolism 2007; 20(10) doi: 10.1515/JPEM.2007.20.10.1059
6
Anuj A Parkash, Animesh Bardoloi, Parul Singla. Metabolic effects of obesity: A review. World Journal of Diabetes 2010; 1(3): 76-88 doi: 10.4239/wjd.v1.i3.76
7
Daniel Zamora-Valdés, Guadalupe Ponciano-Rodríguez, Norberto C. Chávez-Tapia, Nahum Méndez-Sánchez. The endocannabinoid system in chronic liver disease. Annals of Hepatology 2005; 4(4) doi: 10.1016/S1665-2681(19)32047-2
8
Marcin Krawczyk, Leonilde Bonfrate, Piero Portincasa. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 2010; 24(5) doi: 10.1016/j.bpg.2010.08.005
9
Nahum Méndez-Sánchez, Norberto C. Chávez-Tapia, Roberto Medina-Santillán, Antonio R. Villa, Karla Sánchez-Lara, Guadalupe Ponciano-Rodríguez, Martha H. Ramos, Misael Uribe. The Efficacy of Adipokines and Indices of Metabolic Syndrome as Predictors of Severe Obesity-Related Hepatic Steatosis. Digestive Diseases and Sciences 2006; 51(10) doi: 10.1007/s10620-006-9093-5
10
Shreya C Pal, Nahum Méndez-Sánchez. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World Journal of Gastroenterology 2023; 29(25): 3999-4008 doi: 10.3748/wjg.v29.i25.3999
11
Shoba Shetty, Christine M. Kusminski, Philipp E. Scherer. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends in Pharmacological Sciences 2009; 30(5) doi: 10.1016/j.tips.2009.02.004
12
Javier Lizardi-Cervera, Norberto C. Chavez-Tapia, Oliver Pérez-Bautista, Martha H. Ramos, Misael Uribe. Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk. Digestive Diseases and Sciences 2007; 52(9) doi: 10.1007/s10620-006-9262-6
13
Anna Katharine Hindle, Claire Edwards, Alisha Mendonsa, Marcos Rojkind, Tim McCaffrey, Sidney Fu, Fred Brody. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surgical Endoscopy 2010; 24(7) doi: 10.1007/s00464-009-0808-5
14
Ashraf Elfakhry, Ehab Abdel-Khalek, Sahar El-Gharabawy, Eman El-Tanaihy, Azza Abdelbaky. Predictive value of the adiponectin to leptin ratio for diagnosis of steatohepatitis in patients with nonalcoholic fatty liver disease. Egyptian Liver Journal 2013; 3(2) doi: 10.1097/01.ELX.0000427107.63804.34
15
P. Haentjens, D. Massaad, H. Reynaert, E. Peeters, A. Van Meerhaeghe, S. Vinken, K. Poppe, B. Velkeniers. IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS. Acta Clinica Belgica 2009; 64(6) doi: 10.1179/acb.2009.084
16
Eman F. Khaleel, Ghada A. Abdel-Aleem. Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. Archives of Physiology and Biochemistry 2019; 125(1) doi: 10.1080/13813455.2018.1437638
17
G. C. B. Magalhães, F. M. Feitoza, S. B. Moreira, A. V. Carmo, F. J. D. Souto, S. R. L. Reis, M. S. F. Martins, M. H. G. Gomes da Silva. Hypoadiponectinaemia in nonalcoholic fatty liver disease obese women is associated with infrequent intake of dietary sucrose and fatty foods. Journal of Human Nutrition and Dietetics 2014; 27(s2) doi: 10.1111/jhn.12110
18
Sandra Maria Barbalho, Nahum Méndez-Sánchez, Lucas Fornari Laurindo. AdipoRon and ADP355, adiponectin receptor agonists, in Metabolic-associated Fatty Liver Disease (MAFLD) and Nonalcoholic Steatohepatitis (NASH): A systematic review. Biochemical Pharmacology 2023; 218 doi: 10.1016/j.bcp.2023.115871
19
Ylse Gutierrez-Grobe, Israel Villalobos-Blasquez, Karla Sánchez-Lara, Antonio R. Villa, Guadalupe Ponciano-Rodríguez, Martha H. Ramos, Norberto C. Chavez-Tapia, Misael Uribe, Nahum Méndez-Sánchez. High ghrelin and obestatin levels and low risk of developing fatty liver. Annals of Hepatology 2010; 9(1) doi: 10.1016/S1665-2681(19)31679-5
20
Sophie Clément, Cristiana Juge-Aubry, Antonino Sgroi, Stéphanie Conzelmann, Valerio Pazienza, Brigitte Pittet-Cuenod, Christoph A. Meier, Francesco Negro. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 2008; 48(3) doi: 10.1002/hep.22404
21
Maud Lemoine, Vlad Ratziu, Minji Kim, Mustapha Maachi, Dominique Wendum, François Paye, Jean Philippe Bastard, Raoul Poupon, Chantal Housset, Jacqueline Capeau, Lawrence Serfaty. Serum adipokine levels predictive of liver injury in non‐alcoholic fatty liver disease. Liver International 2009; 29(9) doi: 10.1111/j.1478-3231.2009.02022.x
22
Nahum Méndez-Sánchez, Antonio R. Villa, Norberto C. Chávez-Tapia, Guadalupe Ponciano-Rodriguez, Paloma Almeda-Valdés, Daniela González, Misael Uribe. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Annals of Hepatology 2005; 4(1) doi: 10.1016/S1665-2681(19)32086-1
23
Ancha Baranova, Manpreet Randhawa, Mohammed Jarrar, Zobair M Younossi. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics 2007; 7(2) doi: 10.1586/14737159.7.2.195
24
Misael Uribe, Daniel Zamora-Valdés, Mucio Moreno-Portillo, Luisa Bermejo-Martínez, Raúl Pichardo-Bahena, Héctor A. Baptista-González, Guadalupe Ponciano-Rodríguez, Martha H. Uribe, Roberto Medina-Santillán, Nahum Méndez-Sánchez. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Annals of Hepatology 2008; 7(1) doi: 10.1016/S1665-2681(19)31890-3
25
Fei‐Peng Lee, Chih‐Yu Jen, Chih‐Cheng Chang, Ying Chou, Heng Lin, Chih‐Ming Chou, Shu‐Hui Juan. Mechanisms of adiponectin‐mediated COX‐2 induction and protection against iron injury in mouse hepatocytes. Journal of Cellular Physiology 2010; 224(3) doi: 10.1002/jcp.22192
26
Ingrid J. Hickman, Graeme A. Macdonald. Impact of Diabetes on the Severity of Liver Disease. The American Journal of Medicine 2007; 120(10) doi: 10.1016/j.amjmed.2007.03.025
27
S. Disthabanchong, K. Niticharoenpong, P. Radinahamed, W. Stitchantrakul, B. Ongphiphadhanakul, S. Hongeng. Metabolic acidosis lowers circulating adiponectin through inhibition of adiponectin gene transcription. Nephrology Dialysis Transplantation 2011; 26(2) doi: 10.1093/ndt/gfq410
28
Suenje Fischer, Anne Navarrete Santos, René Thieme, Nicole Ramin, Bernd Fischer. Adiponectin Stimulates Glucose Uptake in Rabbit Blastocysts1. Biology of Reproduction 2010; 83(5) doi: 10.1095/biolreprod.110.084665
29
Huiting Gao, Zhigang Zeng, Han Zhang, Xiaoli Zhou, Lichang Guan, Weiping Deng, Lishu Xu. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. Biological & Pharmaceutical Bulletin 2015; 38(5) doi: 10.1248/bpb.b14-00505
30
Mariana V. Machado, João Coutinho, Fátima Carepa, Adília Costa, Helena Proença, Helena Cortez-Pinto. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2012; 24(10) doi: 10.1097/MEG.0b013e32835609b0
31
James J DiNicolantonio, Mark McCarty. Autophagy-induced degradation of Notch1, achieved through intermittent fasting, may promote beta cell neogenesis: implications for reversal of type 2 diabetes. Open Heart 2019; 6(1) doi: 10.1136/openhrt-2019-001028
32
A. Federico, M. Trappoliere, C. Loguercio. Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives. Digestive and Liver Disease 2006; 38(11) doi: 10.1016/j.dld.2006.04.009
33
Magali Gary-Bobo, Ghizlane Elachouri, Jean François Gallas, Philip Janiak, Pietro Marini, Christine Ravinet-Trillou, Michèle Chabbert, Noël Cruccioli, Christian Pfersdorff, Claude Roque, Michèle Arnone, Tiziano Croci, Philippe Soubrié, Florence Oury-Donat, Jean Pierre Maffrand, Bernard Scatton, Frederic Lacheretz, Gérard Le Fur, Jean Marc Herbert, Mohammed Bensaid. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46(1) doi: 10.1002/hep.21641
34
Jie Pan, Yijie Ding, Yan Sun, Qiuyan Li, Tianyi Wei, Yingying Gu, Yujia Zhou, Nengzhi Pang, Lei Pei, Sixi Ma, Mengqi Gao, Ying Xiao, De Hu, Feilong Wu, Lili Yang. Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria. Journal of Clinical Medicine 2023; 12(6) doi: 10.3390/jcm12062126
35
Alessandro Federico, Marco Niosi, Camillo Del Vecchio Blanco, Carmela Loguercio. Emerging drugs for non-alcoholic fatty liver disease. Expert Opinion on Emerging Drugs 2008; 13(1) doi: 10.1517/14728214.13.1.145
36
Tomoyuki Mine, Kyoko Miura, Toshifumi Kajioka, Yoshiro Kitahara. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet. Metabolism 2008; 57(1) doi: 10.1016/j.metabol.2007.08.017
37
Ancha Baranova, Zobair M. Younossi. Adipose Tissue and Adipokines in Health and Disease. Nutrition and Health 2007;  doi: 10.1007/978-1-59745-370-7_22
38
Ernesto Roldan-Valadez, Rafael Favila, Manuel Martínez-López, Misael Uribe, Nahum Méndez-Sánchez. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Annals of Hepatology 2008; 7(3) doi: 10.1016/S1665-2681(19)31850-2
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.